MDIT (MDIT) Stock Price & Analysis
MDIT (MDIT) rose 0.00% to USD 0 as of June 10, 2026 at 19:22 UTC, according to Nexqual real-time market data.
MDIT last closed at USD 0; the session ranged USD 0–0 on volume of 88 shares. Market capitalization is $8,672, with a 52-week range of USD 0–0.01 (PNK). Source: Nexqual, June 10, 2026 at 19:22 UTC.
Key Statistics (as of June 10, 2026 at 19:22 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0.01 |
| Volume | 88 shares |
| Market Cap | $8,672 |
| Exchange | PNK |
Technical Analysis (MDIT)
Nexqual's technical model rates MDIT "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 19:22 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (MDIT)
Wall Street analysts rate MDIT "None", per Nexqual as of June 10, 2026 at 19:22 UTC.
| Consensus Rating | None |
|---|
Earnings (MDIT)
Source: Nexqual, June 10, 2026 at 19:22 UTC.
Financials & Fundamentals (MDIT)
| Total Revenue | $8.13M |
|---|---|
| Revenue Growth (YoY) | +42.00% |
| Gross Margin | +23.71% |
| Operating Margin | -3.97% |
| Profit Margin | -65.49% |
| ROE | -73.70% |
| Debt / Equity | 94 |
| Current Ratio | 1.11 |
| Total Cash | $90,000 |
| Total Debt | $6.05M |
| Free Cash Flow | $-2.44M |
Source: Nexqual, June 10, 2026 at 19:22 UTC.
Financial Health Score (MDIT)
Nexqual rates MDIT's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 19:22 UTC.
| Growth | Strong — Revenue +42% YoY (latest Q) |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Mixed — $90K cash vs $6M debt |
| Cash Flow | Weak — FCF negative: -$2M, burning cash |
| Efficiency | Critical — ROE -74%, ROA -13.7% |
Ownership (MDIT)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 86.72M |
| Float | 17.31M |
Source: Nexqual, June 10, 2026 at 19:22 UTC.
Leadership (MDIT)
MDIT is led by Jeffrey Rencher (age 58), Chief Marketing & Business Development Officer, per Nexqual as of June 10, 2026 at 19:22 UTC.
| Chief Marketing & Business Development Officer | Jeffrey Rencher (age 58) |
|---|
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RGDXQ | RESPONSE GENETICS INC | USD 0 | ▲ 0% |
| FPMI | FLUOROPHARMA MEDICAL INC | USD 0 | ▲ 0% |
| EVARF | LOMBARD MED INC | USD 0 | ▲ 0% |
| NMXS | Net Medical Xpress Solutions, I | USD 0 | ▲ 0% |
| APVS | APPLIED VISUAL SCIENCES INC | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 19:22 UTC. This page is informational and not investment advice.